Literature DB >> 27522360

Changes of serum Mir-217 and the correlation with the severity in type 2 diabetes patients with different stages of diabetic kidney disease.

Ying Shao1, Huiwen Ren1, Chuan Lv2, Xiaoyu Ma3, Can Wu1, Qiuyue Wang4.   

Abstract

The aim of this study is to investigate the correlation between serum microRNA-217 and the severity of diabetic kidney disease determined by albuminuria. Four hundred ninety five type 2 diabetes patients were divided into three groups: normoalbuminuric group, microalbuminuric group, and macroalbuminuric group. Serum microRNA-217 levels were validated by real-time polymerase chain reaction. Serum silent information regulator 1, Hypoxia-inducible factor-1α and vascular endothelial growth factor were determined by enzyme-linked immunosorbent assay. Compared with control, serum microRNA-217 levels were significantly increased in type 2 diabetes patients and gradually increased in patients of normoalbuminuric, microalbuminuric, and macroalbuminuric groups (P < 0.01). Moreover, increased levels of serum microRNA-217, hypoxia-inducible factor-1α, vascular endothelial growth factor, diabetes mellitus duration, fasting blood glucose, fasting insulin, homeostasis model assessment for insulin resistance, glycated hemoglobin, low-density lipoprotein, total cholesterol, triglyceride, uric acid, serum creatinine, blood urea nitrogen, and decreased levels of serum silent information regulator 1 and high-density lipoprotein were significantly correlated with Ln(ACR) (P < 0.05). In addition, serum microRNA-217 was positively correlated with diabetes mellitus duration, homeostasis model assessment for insulin resistance, glycated hemoglobin, Ln(ACR), low-density lipoprotein, total cholesterol, triglyceride, uric acid, serum creatinine, blood urea nitrogen, hypoxia-inducible factor-1α, vascular endothelial growth factor (P < 0.05), and negatively correlated with serum silent information regulator 1 (P = 0.002). Our findings suggest that microRNA-217 may have an association with the development of proteinuria in type 2 diabetes patients. Serum microRNA-217 may be involved in the development of diabetic kidney disease by promoting chronic inflammation, renal fibrosis, and angiogenesis.

Entities:  

Keywords:  Albuminuria; Diabetic kidney disease; Hypoxia-inducible factor-1α; Serum microRNA-217; Silent information regulator 1

Mesh:

Substances:

Year:  2016        PMID: 27522360     DOI: 10.1007/s12020-016-1069-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  33 in total

Review 1.  Role of microRNAs in endothelial cell pathophysiology.

Authors:  Teresa Staszel; Barbara Zapała; Anna Polus; Anna Sadakierska-Chudy; Beata Kieć-Wilk; Ewa Stępień; Iwona Wybrańska; Monika Chojnacka; Aldona Dembińska-Kieć
Journal:  Pol Arch Med Wewn       Date:  2011-10

Review 2.  Fructose and uric acid in diabetic nephropathy.

Authors:  Petter Bjornstad; Miguel A Lanaspa; Takuji Ishimoto; Tomoki Kosugi; Shinji Kume; Diana Jalal; David M Maahs; Janet K Snell-Bergeon; Richard J Johnson; Takahiko Nakagawa
Journal:  Diabetologia       Date:  2015-06-07       Impact factor: 10.122

3.  High Glucose Up-regulates ADAM17 through HIF-1α in Mesangial Cells.

Authors:  Renzhong Li; Lalita Uttarwar; Bo Gao; Martine Charbonneau; Yixuan Shi; John S D Chan; Claire M Dubois; Joan C Krepinsky
Journal:  J Biol Chem       Date:  2015-07-14       Impact factor: 5.157

Review 4.  MicroRNA regulatory networks in human adipose tissue and obesity.

Authors:  Peter Arner; Agné Kulyté
Journal:  Nat Rev Endocrinol       Date:  2015-03-03       Impact factor: 43.330

5.  Circulating miR-130b mediates metabolic crosstalk between fat and muscle in overweight/obesity.

Authors:  Yu-cheng Wang; Yuying Li; Xin-yi Wang; Duo Zhang; Huihui Zhang; Qi Wu; Yu-qing He; Jian-ying Wang; Lian Zhang; Hongfeng Xia; Jun Yan; Xihua Li; Hao Ying
Journal:  Diabetologia       Date:  2013-07-19       Impact factor: 10.122

Review 6.  Recent advances in animal models of diabetic nephropathy.

Authors:  Boris Betz; Bryan R Conway
Journal:  Nephron Exp Nephrol       Date:  2014-07-12

7.  Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization.

Authors:  Francisco J Ortega; Josep M Mercader; José María Moreno-Navarrete; Oscar Rovira; Ester Guerra; Eduardo Esteve; Gemma Xifra; Cristina Martínez; Wifredo Ricart; Jennifer Rieusset; Sophie Rome; Monika Karczewska-Kupczewska; Marek Straczkowski; José Manuel Fernández-Real
Journal:  Diabetes Care       Date:  2014-01-29       Impact factor: 19.112

Review 8.  Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy.

Authors:  Takahiko Nakagawa; Waichi Sato; Tomoki Kosugi; Richard J Johnson
Journal:  J Diabetes Res       Date:  2013-12-09       Impact factor: 4.011

Review 9.  Renal protective effect of sirtuin 1.

Authors:  Yi-jun Dong; Nian Liu; Zhi Xiao; Tao Sun; Shu-hui Wu; Wei-xia Sun; Zhong-gao Xu; Hang Yuan
Journal:  J Diabetes Res       Date:  2014-10-16       Impact factor: 4.011

10.  MicroRNA-217 promotes angiogenesis of human cytomegalovirus-infected endothelial cells through downregulation of SIRT1 and FOXO3A.

Authors:  Shanchao Zhang; Lei Liu; Ruijin Wang; Houzhen Tuo; Yanjun Guo; Li Yi; Dexin Wang; Jiawei Wang
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

View more
  19 in total

Review 1.  Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors.

Authors:  Milton Packer
Journal:  J Am Soc Nephrol       Date:  2020-04-10       Impact factor: 10.121

2.  Emerging role of miRNAs in renal fibrosis.

Authors:  Youling Fan; Hongtao Chen; Zhenxing Huang; Hong Zheng; Jun Zhou
Journal:  RNA Biol       Date:  2019-09-24       Impact factor: 4.652

3.  Proinflammatory-factors-carrying-microvesicles from monocytes induced by high glucose enhance the activation of HIF/VEGF pathway in human renal mesangial cells.

Authors:  Mingzhen Li; Jing Yu; Lirong Sun
Journal:  Int J Clin Exp Pathol       Date:  2019-08-01

Review 4.  The role of uric acid in mineral bone disorders in chronic kidney disease.

Authors:  Baris Afsar; Alan A Sag; Cinar Oztosun; Masanari Kuwabara; Mario Cozzolino; Adrian Covic; Mehmet Kanbay
Journal:  J Nephrol       Date:  2019-04-27       Impact factor: 3.902

5.  Expression of miR-217 and HIF-1α/VEGF pathway in patients with diabetic foot ulcer and its effect on angiogenesis of diabetic foot ulcer rats.

Authors:  C-J Lin; Y-M Lan; M-Q Ou; L-Q Ji; S-D Lin
Journal:  J Endocrinol Invest       Date:  2019-05-11       Impact factor: 4.256

6.  Circulating microRNA-1a is a biomarker of Graves' disease patients with atrial fibrillation.

Authors:  Fang Wang; Sheng-Jie Zhang; Xuan Yao; Dong-Mei Tian; Ke-Qin Zhang; Dun-Min She; Fei-Fan Guo; Qi-Wei Zhai; Hao Ying; Ying Xue
Journal:  Endocrine       Date:  2017-05-25       Impact factor: 3.633

7.  Hydrogen Sulfide Inhibits High Glucose-Induced sFlt-1 Production via Decreasing ADAM17 Expression in 3T3-L1 Adipocytes.

Authors:  Tian-Xiao Hu; Gang Wang; Wei Wu; Lu Gao; Qing-Ying Tan; Jing Wang
Journal:  Int J Endocrinol       Date:  2017-06-27       Impact factor: 3.257

Review 8.  MicroRNA and Microvascular Complications of Diabetes.

Authors:  F Barutta; S Bellini; R Mastrocola; G Bruno; G Gruden
Journal:  Int J Endocrinol       Date:  2018-03-07       Impact factor: 3.257

9.  MiR-802 causes nephropathy by suppressing NF-κB-repressing factor in obese mice and human.

Authors:  Da Sun; Jia Chen; Wei Wu; Ju Tang; Li Luo; Kun Zhang; Libo Jin; Sue Lin; Yitian Gao; Xiaoqing Yan; Chi Zhang
Journal:  J Cell Mol Med       Date:  2019-02-07       Impact factor: 5.310

10.  Expression Profiling and Clinical Significance of Plasma MicroRNAs in Diabetic Nephropathy.

Authors:  Jianqin Wang; Gouqin Wang; Yaojun Liang; Xiaochun Zhou
Journal:  J Diabetes Res       Date:  2019-05-14       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.